When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Bristol-Myers Squibb(NYSE: BMY) isn't having a great year. The big pharma stock has spent most of 2019 in negative territory. Many investors weren't happy with the decision to acquire Celgene(NASDAQ: CELG). And BMS has experienced some clinical-study disappointments for its blockbuster cancer drug, Opdivo.
But is Bristol-Myers Squibb still a smart pick for long-term investors? Let's look at the reasons to consider buying the stock and the reasons to avoid it.